IDEAYA Biosciences Inc
NASDAQ:IDYA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.79
47.13
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
IDEAYA Biosciences Inc
IDEAYA Biosciences Inc
Common Stock
IDEAYA Biosciences Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IDEAYA Biosciences Inc
NASDAQ:IDYA
|
Common Stock
$9k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Common Stock
$18m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Common Stock
$33.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Common Stock
$2.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Common Stock
$101.8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
IDEAYA Biosciences Inc
Glance View
IDEAYA Biosciences Inc. is a beacon of innovation in the burgeoning field of precision oncology, focused primarily on advancing synthetic lethality - a cutting-edge approach to cancer therapy. Founded in 2015 and headquartered in South San Francisco, California, the company is deeply entrenched in the research and development of targeted therapies to combat genetically defined cancers. The core strategy revolves around discovering and developing small molecule inhibitors that precisely align with defined genetic alterations in cancer patients. By doing so, IDEAYA aims to exploit the weaknesses in specific cancer cells while sparing normal, healthy cells, thereby enhancing treatment efficacy and minimizing adverse effects. This targeted approach represents a significant shift from traditional broad-spectrum chemotherapy, offering a more personalized and efficient treatment pathway. In terms of revenue generation, IDEAYA operates primarily through collaborations and partnerships with larger pharmaceutical companies, which are attracted by its robust pipeline and innovative approach. These strategic alliances often involve milestone payments, research funding, and potential royalties on future sales. Furthermore, IDEAYA occasionally benefits from upfront payments when entering these collaborations, adding to its revenue stream. The company's business model is not solely reliant on direct sales of developed therapies but on leveraging its scientific prowess to create valuable partnership opportunities. By effectively bridging the gap between research and clinical application, IDEAYA captivates not only the interest of the pharmaceutical giants but also the investment community, eager to back a venture at the frontier of precision cancer treatment.
See Also
What is IDEAYA Biosciences Inc's Common Stock?
Common Stock
9k
USD
Based on the financial report for Sep 30, 2024, IDEAYA Biosciences Inc's Common Stock amounts to 9k USD.
You don't have any saved screeners yet
